Ah Equity Partners Lsv Ii, L.L.C. Erasca, Inc. Transaction History
Ah Equity Partners Lsv Ii, L.L.C.
- $95.6 Million
- Q3 2023
A detailed history of Ah Equity Partners Lsv Ii, L.L.C. transactions in Erasca, Inc. stock. As of the latest transaction made, Ah Equity Partners Lsv Ii, L.L.C. holds 312,500 shares of ERAS stock, worth $912,500. This represents 0.64% of its overall portfolio holdings.
Number of Shares
312,500
Previous 312,500
-0.0%
Holding current value
$912,500
Previous $862,000
28.65%
% of portfolio
0.64%
Previous 0.89%
Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
141Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$56.6 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$49.1 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$47.4 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$40.2 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$38.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $357M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...